191 related articles for article (PubMed ID: 23838318)
21. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
22. Immune profiling of human prostate epithelial cells determined by expression of p38/TRAF-6/ERK MAP kinases pathways.
Bouraoui Y; Achour M; Royuela M; Oueslati R
Kaohsiung J Med Sci; 2018 Mar; 34(3):125-133. PubMed ID: 29475459
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
24. [Expression of ERK1/2 MAPK signaling transduction pathway in esophageal cancers in Kazakh patients].
Zheng ST; Liu T; Middottuersun A; Huo Q; Liu Q; Huang CG; Feng JG; Lü GD; Wang X; Lin RY; Sheyhidin I; Lu XM
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):421-5. PubMed ID: 21875481
[TBL] [Abstract][Full Text] [Related]
25. Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro.
Guo TT; Yu YN; Yip GW; Matsumoto K; Bay BH
Anat Rec (Hoboken); 2013 Jun; 296(6):891-8. PubMed ID: 23613305
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
27. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
28. [Effects of extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activation on proliferation and cell cycle associated genes in human colon cancer cells].
Wang X; Lu R; Fang JY
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(14):982-6. PubMed ID: 17650425
[TBL] [Abstract][Full Text] [Related]
29. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
30. Y-box protein 1 stimulates mesangial cell proliferation via activation of ERK1/2.
Feng Q; Huang S; Zhang A; Chen Q; Guo X; Chen R; Yang T
Nephron Exp Nephrol; 2009; 113(1):e16-25. PubMed ID: 19590238
[TBL] [Abstract][Full Text] [Related]
31. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
32. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells.
Basaki Y; Taguchi K; Izumi H; Murakami Y; Kubo T; Hosoi F; Watari K; Nakano K; Kawaguchi H; Ohno S; Kohno K; Ono M; Kuwano M
Eur J Cancer; 2010 Mar; 46(5):954-65. PubMed ID: 20079629
[TBL] [Abstract][Full Text] [Related]
33. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
Astanehe A; Finkbeiner MR; Hojabrpour P; To K; Fotovati A; Shadeo A; Stratford AL; Lam WL; Berquin IM; Duronio V; Dunn SE
Oncogene; 2009 Jun; 28(25):2406-18. PubMed ID: 19430491
[TBL] [Abstract][Full Text] [Related]
34. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway.
Li LB; Goleva E; Hall CF; Ou LS; Leung DY
J Allergy Clin Immunol; 2004 Nov; 114(5):1059-69. PubMed ID: 15536411
[TBL] [Abstract][Full Text] [Related]
35. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
Law JH; Li Y; To K; Wang M; Astanehe A; Lambie K; Dhillon J; Jones SJ; Gleave ME; Eaves CJ; Dunn SE
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844753
[TBL] [Abstract][Full Text] [Related]
36. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
[TBL] [Abstract][Full Text] [Related]
37. Active ERK2 is sufficient to mediate growth arrest and differentiation signaling.
Wu PK; Hong SK; Yoon SH; Park JI
FEBS J; 2015 Mar; 282(6):1017-30. PubMed ID: 25639353
[TBL] [Abstract][Full Text] [Related]
38. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation.
Shiota M; Song Y; Yokomizo A; Kiyoshima K; Tada Y; Uchino H; Uchiumi T; Inokuchi J; Oda Y; Kuroiwa K; Tatsugami K; Naito S
Clin Cancer Res; 2010 Dec; 16(23):5654-63. PubMed ID: 21138866
[TBL] [Abstract][Full Text] [Related]
39. Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma.
Hoffmann K; Shibo L; Xiao Z; Longerich T; Büchler MW; Schemmer P
Anticancer Res; 2011 Nov; 31(11):3883-90. PubMed ID: 22110214
[TBL] [Abstract][Full Text] [Related]
40. Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells.
Lee JT; Steelman LS; McCubrey JA
Int J Oncol; 2005 Jun; 26(6):1637-44. PubMed ID: 15870880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
